While many awaited the most significant ruling in healthcare history, Medicaid plans remained optimistic that coverage expansion would continue. But there's a caveat.
After this morning’s Supreme Court ruling regarding the expansion of Medicaid under the Patient Protection and Affordable Care Act, managed Medicaid plans felt some relief knowing they finally could get back to work. The expansion has made the segment a more attractive business prospect.
“It creates universal coverage, ” says Lisa Han, partner with Squire Sanders. “Working healthy folks will come into the category.”
Han says the Court ruled that Congress can indeed pass a law that requires states to expand Medicaid. However, it is unconstitutional for the federal government to take away ALL of a state's Medicaid funds if a state refuses to participate in Medicaid expansion. Refusal to participate in the expansion then would result in only expansion funding being denied.
“Expanding access to Medicaid is a simple matter of equity and basic fairness to the millions of Americans who will be newly insured-some for the first time-when the expansion goes into effect in 2014,” says Margaret Murray, president and CEO of the Association for Community Affiliated Plans. “ACAP has supported the health reform law from the very beginning, and Safety Net Health Plans have been preparing to expand their capacity to accommodate new populations that will be eligible in 2014.”
Unplugging the expansion of Medicaid would have been far more disruptive to the healthcare market than a decision to strike down the individual mandate would have been. The Court ruled that a Medicaid expansion could be an unconstitutional federal coercion of the states, but the expansion does not have a penalty large enough to pass that threshold.
Medicaid by law will expand nationwide to include nearly all individuals with incomes up to 133 percent of the federal poverty level in 2014. States do have the option to expand coverage sooner.
Today the program covers 60 million individuals, including one in four children, but restrictive eligibility results in many low income individuals remaining uninsured. By 2016, Medicaid, along with the Children’s Health Insurance Program, will cover an additional 17 million individuals, mostly low-income adults, leading to a significant reduction in the nation’s uninsured segment of 49 million people.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More